The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0846 GMT - TrumpRx appears to offer lower-volume drugs at reduced prices, mainly for the uninsured, but pricing for newly launched U.S. drugs remains unclear, Vontobel's Stefan Schneider writes in a note. The U.S. administration said late Friday that it could close deals with nine big pharma names, including Roche and Novartis. However, terms remain confidential, limiting deeper analysis, the analyst says. Price cuts seem restricted to Medicaid, which already benefits from heavy discounts. This makes the impact less severe than if Medicare or all U.S. sales were included, he notes. The evolving process allows pharma companies to adjust prices elsewhere, he adds. Novartis and Roche shares are down 0.2% and 0.1%, respectively. (najat.kantouar@wsj.com)

0627 GMT - Samsung Biologics' contract wins could rise sharply with its decision to acquire a U.S. drug production facility, Samsung Securities analyst Keunhee Seo writes in a note. The South Korean biosimilar contract-development-and-manufacturing-organization company has decided to buy a 100% stake in GSK-owned Genome Sciences in Rockville, Md., for $280 million. The U.S. production base with a 60,000-liter annual capacity could lead to a flurry of new CDMO deals between Samsung and big global pharmaceutical clients who prefer U.S. local production, Seo says. The pending Biosecure Act designed for U.S. drugmakers to reduce their reliance on the Chinese supply chain could also help Samsung secure more contract wins, he adds. (kwanwoo.jun@wsj.com)

0216 GMT - IHH Healthcare's associate Fortis Healthcare plans to acquire People Tree Hospital Yeshwantpur in Bengaluru for INR4.3 billion is likely neutral for IHH, CIMB Securities analyst Chun Sung Oong says in a note. The acquisition's estimated earnings impact is limited to about 0.1% of IHH's 2026 forecast earnings and unlikely to affect IHH's net gearing, he says. While the purchase supports Fortis' strategy to expand bed capacity in India, the share price reaction is likely to be muted, he reckons. However, IHH remains CIMB's sector top pick, driven by better earnings visibility in Singapore, improving efficiency in India and rising medical tourism revenue in Malaysia. CIMB maintains a buy rating on IHH and keeps the target price at MYR9.40. Shares are 0.6% higher at MYR8.57.(yingxian.wong@wsj.com)

(END) Dow Jones Newswires

December 22, 2025 04:20 ET (09:20 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.